Advisor to Advent on the acquisition of Zentiva, the European generics business of Sanofi
Date: 2018 Country: Czech Republic (HQ), France, Germany, Great Britain, Italy, Romania, Poland, Slovakia and other European countries Industry: Pharmaceuticals Target: Zentiva Buyer (client): Advent Seller: Sanofi VCP’s role/competence: buy-side M&A advisor
VCP acted as local M&A advisor to Advent on the €1.9bn acquisition of Zentiva, the European generics business of Sanofi, the international pharmaceutical manufacturer
Zentiva was carved out by Sanofi after the strategic decision to refocus from generic drugs
The sale was organised as open auction and attracted the interest of numerous international strategic players and financial sponsors
VCP supported Advent by covering the main markets of Zentiva, by providing crucial market intelligence gathered through our local contact network and by researching for potential add-on opportunities in the CEE region
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.